TOP trial. A randomised phase iii clinical trial of trastuzumab (Herceptin) optimization in patients with locally advanced and/or metastatic breast cancer overexpressing HER2 [human epidermal growth factor receptor 2] after a first line chemotherapy plus trastuzumab.

Trial Profile

TOP trial. A randomised phase iii clinical trial of trastuzumab (Herceptin) optimization in patients with locally advanced and/or metastatic breast cancer overexpressing HER2 [human epidermal growth factor receptor 2] after a first line chemotherapy plus trastuzumab.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms TOP
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jun 2015 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently.
    • 07 Apr 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top